These findings suggest that in CRC patients with low ALDH1L2 expression levels, who may be resistant to radiotherapy, the simultaneous application of TXN inhibitors and radiotherapy may be an effective treatment strategy; this may help improve radiosensitivity, allowing patients to benefit more from treatment. This evidence concerns the gene TXN and colorectal carcinoma.